AP-101

ZURICH, Switzerland, June 24, 2026 AL-S Pharma AG announced positive Phase 2 clinical results for its lead investigational antibody...

ZURICH, Switzerland, March 19, 2026 AL-S Pharma AG announced new Phase 2 clinical data for its lead investigational therapy...